Grand opening celebrates Hi-School Pharmacy’s return to Vancouver, Wash.
VANCOUVER, Wash. — Hi-School Pharmacy celebrated the grand opening of its new store here Monday, marking the chain’s return to the area following a 12-year absence after the company sold 11 stores to Walgreens in 2003. Though the store opened Sept. 20, the ribbon cutting took place at 3 p.m. Monday.
“Many people had asked when we would be back in Clark County,” says John Crawford, Chief Operating Officer. “We are excited to be back, and are very pleased with our new store, as we hope our customers will be.”
The new store has a full-service pharmacy with a drive-up window and a consultation room, as well as an 11,000-sq. ft. variety section and a 6,200-sq. ft. One Stop hardware department. The store is staffed by locals from the Minnehaha community.
“Our mission is to provide customers with convenience combined with superior customer service,” says Jack Holt, owner. “We look forward to becoming a helpful and valuable neighbor to the community, both inside and outside the walls of our store.”
FDA approves Glenmark’s generic Lotrisone
BY DSN STAFF
SILVER SPRING, Md. — The Food and Drug Administration has approved Glenmark Pharmaceuticals’ generic of Lotrisone (betamethasone dipropionate) cream, the company announced Monday.
The cream is indicated to treat such fungal infections as athlete’s foot and ringworm, among others. U.S. sales for the drug in the 12 months ending in September were $82.4 million.
AstraZeneca to acquire biotech company ZS Pharma
LONDON — In a move that will grow its portfolio of treatments for cardiovascular, metabolic and chronic kidney diseases, AstraZeneca announced that it would be acquiring Californian biotech company ZS Pharma to the tune of $2.7 billion.
Based on the company’s presentation accompanying a conference call on the acquisition, AstraZeneca’s focus to be on the treatment ZS Pharma is developing for hyperkalemia, or too much potassium, a side effect of chronic kidney disease, which affects more than 3 million patients in the U.S. The company’s most promising treatment, ZS-9, has completed Phase 2 and Phase 3 trials and is currently undergoing more trials.
The acquisition is expected to close this year, the company said, and will result in ZS Pharma becoming a wholly owned subsidiary of AstraZeneca.
Loading Post Please Wait...